• Marc E. Lenaerts
  • James R. CouchJr.


Headache is one of the most common complaints of patients seeking medical attention. There are several important indications to warrant investigation of a headache: a patient’s first or worst headache; a recent change in the patient’s headache pattern; new neurologic findings; no response to treatment; and symptoms that do not correspond to a primary headache such as migraine, tension-type, or cluster [1].


Cluster Headache Trigeminal Neuralgia Giant Cell Arteritis Migraine Patient Migraine With Aura 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Couch JR: Headache to worry about. Med Clin North Am 1993, 77: 141–167.PubMedGoogle Scholar
  2. 2.
    Rasmussen BK, Jensen R, Schroll M, Olesen J: Epidemiology of headache in a general population—a prevalence study. J Clin Epidemiol 1991, 44 (11): 1147–1157.PubMedCrossRefGoogle Scholar
  3. 3.
    Lipton RB, Stewart WF: Migraine in the United States: a review of epidemiology and health care use. Neurology 1993, 43: S6 - S10.PubMedGoogle Scholar
  4. 4.
    Schwartz BS, Stewart WF, Simon D, Lipton RB: Epidemiology of tension-type headache. JAMA 1998, 279 (5): 381–383.PubMedCrossRefGoogle Scholar
  5. 5.
    Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988, 7: 1–96.Google Scholar
  6. 6.
    Launer LJ, Terwindt GM, Ferrari MD: The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999, 53 (3): 537–542.PubMedCrossRefGoogle Scholar
  7. 7.
    Stewart WF, Linet MS, Celentano DD, et al.: Age-and sex-specific incidence rates of migraine with and without aura. Am J Epidemiol 1991, 134:1111–1120.Google Scholar
  8. 8.
    S. Stewart WF, Lipton RB, Liberman J: Variation in migraine prevalence by race. Neurology 1996, 47 (1): 52–59.PubMedCrossRefGoogle Scholar
  9. 9.
    Lipton RB, Stewart WF: Acute migraine therapy. Headache 1999, 39: S20 - S26.CrossRefGoogle Scholar
  10. 10.
    Hu XH, Markson LE, Lipton RB, et al.: Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999, 159(8):813–818.Google Scholar
  11. 11.
    Terwindt GM, Ferrari MD, Tijhuis M, et al.: The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000, 55:624–629.Google Scholar
  12. 12.
    Couch JR: Complexities of presentation and pathogenesis of migraine headache. In Treating the Headache Patient. Edited by Cady RK, Fox AW. New York: Marcel Dekker; 1995.Google Scholar
  13. 13.
    Lenaerts M: Migraine and epilepsy: comorbidity and temporal relationship. Paper presented at: Ninth Congress of the International Society; June 1999; Barcelona, Spain.Google Scholar
  14. 14.
    Merikangas KR, Merikangas JR, Angst J: Headache syndromes and psychiatric disorders: association and familial transmission. J Psychiatr Res 1993, 27: 197–210.PubMedCrossRefGoogle Scholar
  15. 15.
    Olesen J, Tfelt-Hansen P, Welch KMA: The Headaches. New York: Raven Press; 1993: 256–266.Google Scholar
  16. 16.
    Lennox WG, Gibbs EL, Gibbs FA: Effect of ergotamine tartrate on the cerebral circulation of man. J Pharmacol Exp Ther 1935, 53: 113.Google Scholar
  17. 17.
    Ledo AAP: Spreading depression of activity in cerebral cortex. J Neurophysiol 1944, 7: 359–390.Google Scholar
  18. 18.
    Lashley KS: Patterns of cerebral integration indicated by scotomas of migraine. Arch Neurol Psychiat 1941, 46: 331.CrossRefGoogle Scholar
  19. 19.
    Lauritzen M, Olesen J: Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain 1984, 107: 447–461.PubMedCrossRefGoogle Scholar
  20. 20.
    Olesen J, Friberg L, Olsen TS, et al.: Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990, 28:791–798.Google Scholar
  21. 21.
    Cutrer FM, Sorensen AG, Weisskoff RM, et al.: Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998, 43:25–31.Google Scholar
  22. 22.
    Woods RP, Iacoboni M, Mazziotta JC: Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994, 331: 1689–1692.PubMedCrossRefGoogle Scholar
  23. 23.
    Weiner C, May A, Limmroth V, et al.: Brain stem activation in spontaneous human migraine attacks. Nat Med 1995, 1:658–660.Google Scholar
  24. 24.
    Raskin NH, Hosobuchi Y, Lamb S: Headache may arise from perturbation of brain. Headache 1987, 27: 416–420.PubMedCrossRefGoogle Scholar
  25. 25.
    Goadsby PJ, Edvinsson L, Ekman R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990, 28: 183–187.PubMedCrossRefGoogle Scholar
  26. 26.
    Moskowitz MA: Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992, 13: 307–311.PubMedCrossRefGoogle Scholar
  27. 27.
    Goadsby PJ, Zagami AS, Lambert GA: Neural processing of craniovascular pain: a synthesis of the central-structures involved in migraine. Headache 1991, 31: 365–371.PubMedCrossRefGoogle Scholar
  28. 28.
    Schoenen REF: Contingent negative variation: methods and potential interest in headache. Cephalalgia 1993, 13 (1): 28–32.PubMedCrossRefGoogle Scholar
  29. 29.
    tlfra J, Cecchini AP, DePasqua V, et al.: Visual evoked potentials during long periods of pattern-reversal stimulation in migraine. Brain 1998, 121:233–241.Google Scholar
  30. 30.
    Wang W, Lenaerts M, Schoenen J: Reduced habituation of pattern-reversal visual evoked responses in migraine. Paper presented at: International Conference of the European Headache Federation; June 1994; Liege, Belgium.Google Scholar
  31. 31.
    Welch KMA, Cao Y, Aurora S, et al.: MRI of the occipital cortex, red nucleus, and substantia nigra during visual aura of migraine. Neurology 1998, 51:1465–1469.Google Scholar
  32. 32.
    Joutel A, Bousser MG, Biousse V, et al.: A gene for familial hemiplegic migraine maps to chromosome 19. Nat Genet 1993, 5:40–45.Google Scholar
  33. 33.
    Ophoff RA, Terwindt GM, Vergouwe MN, et al.: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Ce11 1996, 87:543–552.Google Scholar
  34. 34.
    Barbiroli B Montagna P, Cortelli P, et al.: Abnormal brain and muscle metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992, 42:1209–1214.Google Scholar
  35. 35.
    Welch KM, Levine SR, D’Andrea G, et al.: Preliminary observation on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 1989, 39:538–541.Google Scholar
  36. 36.
    Ferrari MD, Odink J, Tapparelli C, et al.: Serotonin metabolism in migraine. Neurology 1989, 39:1239–1242.Google Scholar
  37. 37.
    Humphrey PPA: 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991, 238:S38–S44.Google Scholar
  38. 38.
    Ferrari MD: Systemic biochemistry. In The Headaches. Edited by Olesen J, Tfelt-Hansen P, Welch KMA. New York: Raven Press; 1993: 179–183.Google Scholar
  39. 39.
    Parsons AA, Whalley ET: Characterization of the 5-HT receptor which mediates contraction of the human isolated basilar artery. Cephalalgia 1989, 9 (S9): 47–51.PubMedGoogle Scholar
  40. 40.
    Fozard JR, Kalkman HO: 5-HT in nervous system disease and migraine. Curr Opin Neural Neurosurg 1992, 5 (4): 496–502.Google Scholar
  41. 41.
    Peroutka SJ: Antimigraine drug interactions with serotonin receptor subtypes in human brain. Ann Neural 1988, 23 (5): 500–504.CrossRefGoogle Scholar
  42. 42.
    Peroutka SJ: Dopamine and migraine. Neurology 1997, 49 (3): 650–656.PubMedCrossRefGoogle Scholar
  43. 43.
    Goadsby PJ: The pathophysiology of primary headache. In Headache in Clinical Practice. Edited by Silberstein SD, Lipton RB, Goadsby PJ. Oxford: ISIS Medical Media; 1998.Google Scholar
  44. 44.
    Storer RJ, Goadsby PJ: Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience 1999, 90 (4): 1371–1376.PubMedCrossRefGoogle Scholar
  45. 45.
    Schoenen J, Sianard-Gainko J, Lenaerts M: Blood magnesium levels in migraine. Cephalalgia 1991, 11: 97–99.PubMedCrossRefGoogle Scholar
  46. 46.
    Ramadan NM, Halvorson H, Vande-Linde A, et al. Low brain magnesium level in migraine. Headache 1989, 29 (7): 416–419.PubMedCrossRefGoogle Scholar
  47. 47.
    Somerville BM: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972, 22: 355–365.PubMedCrossRefGoogle Scholar
  48. 48.
    Welch KMA, Darnley D, Simkins RT: The role of estrogens in migraine: a review and hypothesis. Cephalalgia 1984, 4: 227–236.PubMedCrossRefGoogle Scholar
  49. 49.
    Mathew NT, Kailasam J, Meadors L, et al.: Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache 2000, 40(9):720–723.Google Scholar
  50. 50.
    Goadsby PJ, Hargreaves RJ: Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 2000, 55: S8 - S14.PubMedGoogle Scholar
  51. 51.
    Goadsby PJ: The scientific basis of medication choice in symptomatic migraine treatment. Can J Neurol Sci 1999, 26: 20–26.Google Scholar
  52. 52.
    Humphrey PP, Feniuk W: Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991, 12: 444–446.PubMedCrossRefGoogle Scholar
  53. 53.
    Silberstein SD: Rizatriptan versus usual care in long-term treatment of migraine. Neurology 2000, 55: S25 - S28.PubMedCrossRefGoogle Scholar
  54. 54.
    Solomon GD, Cady RK, Klapper JA, et al.: Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997, 49:1219–1225.Google Scholar
  55. 55.
    Nappi G, Sicuteri F, Byrne M, et al.: Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994, 241:138–144.Google Scholar
  56. 56.
    Sargent J, Kirchner J, Davis R, Kirkhart B: Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995, 45: S10 - S14.PubMedGoogle Scholar
  57. 57.
    Tfelt-Hansen P, Ryan RE Jr: Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. Neurology 2000, 55: S19 - S24.PubMedGoogle Scholar
  58. 58.
    The International 311C90 Long-term Study Group: The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998, 38: 173–183.Google Scholar
  59. 59.
    Cady RK, Lipton RB, Hall C, et al.: Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000, 40(10):792–797.Google Scholar
  60. 60.
    Lipton RB, Stewart WF, Cady R, et al.: Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000, 40(10):1–9.Google Scholar
  61. 61.
    Raskin NH: Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986, 36 (7): 995–997.PubMedCrossRefGoogle Scholar
  62. 62.
    Goadsby PJ: How do the currently used prophylactic agents work in migraine? Cephalalgia 1997, 17: 85–92.PubMedCrossRefGoogle Scholar
  63. 63.
    Breslau N, Merikangas K, Bowden CL: Comorbidity of migraine and major affective disorders. Neurology 1994, 44: S17 - S22.PubMedGoogle Scholar
  64. 64.
    Breslau N, Davis GC, Schultz LR, Peterson EL: Migraine and major depression: a longitudinal study. Headache 1994, 34: 387–393.PubMedCrossRefGoogle Scholar
  65. 65.
    Schoenen J, Jacquy J, Lenaerts M: Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998, 50: 466–470.PubMedCrossRefGoogle Scholar
  66. 66.
    Silberstein SD, Silberstein MM: New concepts in the pathogenesis of headache: migraine versus tension-type headache. Phys Assist 1991, 9: 67–81.Google Scholar
  67. 67.
    Jensen R, Olesen J: Initiating mechanisms of experimentally-induced tension-type headache. Cephalalgia 1996, 16: 175.PubMedCrossRefGoogle Scholar
  68. 68.
    Schoenen J, Sandor P: Headache. In Textbook of Pain, edn 4. Edited by Wall PD, Melzack R. New York: Churchill Livingstone; 1999.Google Scholar
  69. 69.
    Lance JW, Ekbom K: In Cluster Headaches: Mechanism and Management. Edited by Kudrow L. New York: Oxford University Press; 1980: 27–28.Google Scholar
  70. 70.
    Hardebo JE: On pain mechanisms in cluster headache. Headache 1991, 31: 91–106.PubMedCrossRefGoogle Scholar
  71. 71.
    May A, Bahra A, Büchel, et al.: PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 2000, 55:1328–1335.Google Scholar
  72. 72.
    Lenaerts M, Couch JR: Trigeminal neuralgia. Emedicine [serial online]. 2001. Available at: http://www.emedicine.com/oph/NEUROLOGIC_DISORDERS.htm. Accessed January 25, 2001.Google Scholar
  73. 73.
    Blom S: Trigeminal neuralgia: a treatment with a new anticonvulsant drug. Lancet 1962, 1: 839–840.PubMedCrossRefGoogle Scholar
  74. 74.
    Fromm GH, Terrence CF, Chattha AS: Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 1984, 15 (3): 240–244.PubMedCrossRefGoogle Scholar
  75. 75.
    McLaughlin MR, Jannetta PJ, Clyde BL, et al.: Microvascular decompression of cranial nerves: lessons learned after 4400 operations. J Neurosurg 1999, 90(1):1–8.Google Scholar
  76. 76.
    Evans RW, Armon C, Frohman EM, Goodin DS: Assessment: prevention of post-lumbar puncture headaches: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2000, 55: 909–914.PubMedCrossRefGoogle Scholar
  77. 77.
    Lenaerts M, Pepin JL, Tombu S, Schoenen J: No significant effect of an “atraumatic” needle on the incidence of post-lumbar puncture headache or traumatic tap. Cephalalgia 1993, 13: 296–297.PubMedCrossRefGoogle Scholar
  78. 78.
    Williams E, Fawcett W, Jenkins G: Preventing headache after lumbar puncture. Optimism generally quoted for epidural blood patching is unwarranted. BMJ 1998, 317: 1588–1589.PubMedGoogle Scholar
  79. 79.
    Panagopoulos G, Gotsi A, Piaditis G, et al.: Treatment of benign intracranial hypertension with octreotide [abstract]. American Academy of Neurology. 1998.Google Scholar
  80. 80.
    Lou L: Uncommon areas of electrical stimulation for pain relief. Curr Rev Pain 2000, 4 (5): 407–412.PubMedCrossRefGoogle Scholar
  81. 81.
    Weiner RL: The future of peripheral nerve neurostimulation. Neurol Res 2000, 22: 299–303.PubMedGoogle Scholar
  82. 82.
    Sjaastad O, Saunte C, Hovdahl H, et al.: “Cervicogenic” headache: a hypothesis. Cephalalgia 1983, 3(4):249–256Google Scholar
  83. 83.
    Sjaastad O, Fredriksen TA, Pfaffenrath V: Cervicogenic headache: diagnostic criteria. Headache 1990, 30: 725–726.PubMedCrossRefGoogle Scholar
  84. 84.
    Dalessio JD: In Wolfs Headache and Other Head Pain, edn 3. Edited by Dalessio JD, Silberstein SD. New York: Oxford University Press; 1972: 71.Google Scholar
  85. 85.
    Tournier-Lasserve E, Joutel A, Melki J, et al.: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19g12. Nat Genet 1993, 3:256–259.Google Scholar
  86. 86.
    Day JW, Raskin NH: Thunderclap headache: symptom of unruptured cerebral aneurysm. Lancet 1986, 2: 1247–1248.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Marc E. Lenaerts
  • James R. CouchJr.

There are no affiliations available

Personalised recommendations